DLL3 and neoplasm: Clinical correlates reveal that elevated DLL3 expression associates with inferior outcomes in ES-SCLC and predicts enhanced response to DLL3-targeted therapies—patients with >75% DLL3+ tumor cells demonstrated a 38% objective response rate to Rova-T versus 11% in low expressers (29, 55).